A carregar...
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
BACKGROUND: Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by driver mutations in other genes. METHODS: Five hundred and fourteen consecutive patients with NSCLC of all stages were tested...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5995236/ https://ncbi.nlm.nih.gov/pubmed/29899852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25490 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|